deltatrials
No Longer Available EXPANDED_ACCESS NCT01784718

Buphenyl Therapy for Byler's Disease

Compassionate Use of Buphenyl® in the Treatment of Byler's Disease

Sponsor: University of Pittsburgh

Conditions Byler Disease
Interventions Buphenyl
Updated 6 times since 2017 Last updated: Feb 4, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Byler Disease and is currently ongoing. University of Pittsburgh leads this study, which shows 6 recorded versions since 2026 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotNo Longer Available~Feb 2017 – ~Apr 2018 · 14 months · monthly snapshotNo Longer Available~Apr 2018 – ~Jan 2021 · 33 months · monthly snapshotNo Longer Available~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotNo Longer Available~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotNo Longer Available~Sep 2024 – present · 24 months · monthly snapshotNo Longer Available

Change History

6 versions recorded
  1. Sep 2024 — Present [monthly]

    No Longer Available

  2. Jul 2024 — Sep 2024 [monthly]

    No Longer Available

  3. Jan 2021 — Jul 2024 [monthly]

    No Longer Available

  4. Apr 2018 — Jan 2021 [monthly]

    No Longer Available

    Phase: NANone

  5. Feb 2017 — Apr 2018 [monthly]

    No Longer Available NA

Show 1 earlier version
  1. Jan 2017 — Feb 2017 [monthly]

    No Longer Available NA

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Pittsburgh
Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.